Atea Pharmaceuticals
AVIR
133 hedge funds and large institutions have $213M invested in Atea Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 42 increasing their positions, 39 reducing their positions, and 24 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more call options, than puts
Call options by funds: $341K | Put options by funds: $247K
17% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 24
12% more capital invested
Capital invested by funds: $190M → $213M (+$23.1M)
2% more funds holding
Funds holding: 130 → 133 (+3)
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
0.27% more ownership
Funds ownership: 68.14% → 68.4% (+0.27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$8.37M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$7.58M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.04M |
| 4 |
Renaissance Technologies
New York
|
+$2.38M |
| 5 |
Two Sigma Investments
New York
|
+$656K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.34M |
| 3 |
BlackRock
New York
|
-$1.25M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.24M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$959K |
AVIR Hedge Fund Activity: Q2 2023 in Review
133 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q2 2023, worth a combined $213M — up 12% from $190M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AVIR positions and 24 closed out — a net gain of 4 holders — while 42 added to existing stakes and 39 trimmed.
The largest buyer was BML Capital Management, opening a new position worth an estimated $8.37M. The largest seller was Fidelity Investments, cutting an estimated $11.5M.
- 133 institutional investors held Atea Pharmaceuticals (AVIR) as of Q2 2023, up from 130 in Q1 2023.
- Funds reported $213M of Atea Pharmaceuticals stock for Q2 2023, up 12% quarter-over-quarter.
- 28 funds opened new Atea Pharmaceuticals positions in Q2 2023 and 24 closed out, a net change of +4 holders.
- The largest Atea Pharmaceuticals buyer in Q2 2023 was BML Capital Management, an estimated $8.37M added.
- The largest Atea Pharmaceuticals seller in Q2 2023 was Fidelity Investments, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2023.